Westend Capital Management’s AbbVie ABBV Stock Holding History

Westend Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.6K	Hold	127	–	–	0.01%	112
2025 Q4	$29K	Buy	+127	New	+$28.9K	0.01%	105
2025 Q3	–	Sell	-10,530	Closed	-$1.95M	–	254
2025 Q2	$1.95M	Sell	10,530 -599	-5%	-$111K	0.6%	24
2025 Q1	$2.33M	Buy	11,129 +11,097	+34,678%	+$2.16M	0.89%	23
2024 Q4	$5.69K	Hold	32	–	–	﹤0.01%	154
2024 Q3	$6.32K	Hold	32	–	–	﹤0.01%	153
2024 Q2	$5.45K	Sell	32 -53	-62%	-$8.78K	﹤0.01%	136
2024 Q1	$15.5K	Buy	+85	New	+$14.6K	0.01%	103
2016 Q2	–	Sell	-5,675	Closed	-$324K	–	65
2016 Q1	$324K	Buy	5,675 +1,585	+39%	+$88.3K	0.44%	46
2015 Q4	$242K	Sell	4,090 -1,675	-29%	-$96.5K	0.33%	51
2015 Q3	$326K	Buy	5,765 +665	+13%	+$43.3K	0.41%	49
2015 Q2	$347K	Buy	5,100 +645	+14%	+$42.1K	0.4%	49
2015 Q1	$274K	Buy	4,455 +2,130	+92%	+$129K	0.32%	53
2014 Q4	$152K	Buy	2,325 +1,975	+564%	+$125K	0.18%	51
2014 Q3	$19K	Buy	+350	New	+$19.4K	0.02%	71
2014 Q1	–	Sell	-350	Closed	-$18K	–	49
2013 Q4	$18K	Buy	+350	New	+$17.2K	0.02%	77
2013 Q2	$14K	Buy	+350	New	+$15.3K	0.01%	87

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westend Capital Management's ABBV Position: Q1 2026 in Review

Westend Capital Management held its AbbVie (ABBV) position steady in Q1 2026 at 127 shares worth $27.6K. The position accounts for 0.01% of the portfolio, ranked #112.

Westend Capital Management first reported a position in ABBV in Q2 2013 and has held it in 17 quarters since. The position peaked at $2.33M in Q1 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Westend Capital Management held 127 shares of AbbVie worth $27.6K as of Q1 2026.
Westend Capital Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.01% of Westend Capital Management's portfolio in Q1 2026, its #112 holding.
Westend Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 17 quarters since.
Westend Capital Management's AbbVie position peaked at $2.33M in Q1 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Westend Capital Management's 13F filing for Q1 2026, filed 14 Apr 2026.